Abstract Background The five-year overall survival (OS) of advanced-stage ovarian cancer remains nearly 25-35%, although several treatment strategies have evolved to get better outcomes. A considerable amount of heterogeneity and complexity has been seen in ovarian cancer. This study aimed to establish gene signatures that can be used in better prognosis through risk prediction outcome for the survival of ovarian cancer patients. Different studies’ heterogeneity into a single platform is presented to explore the penetrating genes for poor or better survival. The integrative analysis of multiple data sets was done to determine the genes that influence poor or better survival. A total of 6 independent data sets was considered. The Cox Proport...
BackgroundMedian overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4...
Background: Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ...
The expected five-year survival rate from a stage III ovarian cancer diagnosis is a mere 22%; this ...
BACKGROUND: Ovarian cancer has a poor prognosis due to advanced stage at presentation and either int...
Abstract Background Ovarian cancer (OV) is deemed the most lethal gynecological cancer in women. The...
Ovarian carcinoma has the highest mortality rate among gynaecological malignancies. In this project,...
Despite the existence of morphologically indistinguishable disease, patients with advanced ovarian t...
Abstract Background High-grade serious ovarian carcinoma (HGSOC) is a subtype of ovarian cancer with...
Gene expression provides rich information. Successful application has made to predict prognosis of s...
BACKGROUND: Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ...
BackgroundMedian overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4...
Background: Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ...
The objective of this research was to develop a robust gene expression-based prognostic signature an...
BackgroundMedian overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4...
The objective of this research was to develop a robust gene expression-based prognostic signature an...
BackgroundMedian overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4...
Background: Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ...
The expected five-year survival rate from a stage III ovarian cancer diagnosis is a mere 22%; this ...
BACKGROUND: Ovarian cancer has a poor prognosis due to advanced stage at presentation and either int...
Abstract Background Ovarian cancer (OV) is deemed the most lethal gynecological cancer in women. The...
Ovarian carcinoma has the highest mortality rate among gynaecological malignancies. In this project,...
Despite the existence of morphologically indistinguishable disease, patients with advanced ovarian t...
Abstract Background High-grade serious ovarian carcinoma (HGSOC) is a subtype of ovarian cancer with...
Gene expression provides rich information. Successful application has made to predict prognosis of s...
BACKGROUND: Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ...
BackgroundMedian overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4...
Background: Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ...
The objective of this research was to develop a robust gene expression-based prognostic signature an...
BackgroundMedian overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4...
The objective of this research was to develop a robust gene expression-based prognostic signature an...
BackgroundMedian overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4...
Background: Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ...
The expected five-year survival rate from a stage III ovarian cancer diagnosis is a mere 22%; this ...